Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Lacey A Burey"'
Autor:
Anne L van de Ven, Behnaz Abdollahi, Carlos J Martinez, Lacey A Burey, Melissa D Landis, Jenny C Chang, Mauro Ferrari, Hermann B Frieboes
Publikováno v:
New Journal of Physics, Vol 15, Iss 5, p 055004 (2013)
Heterogeneities in the perfusion of solid tumors prevent optimal delivery of nanotherapeutics. Clinical imaging protocols for obtaining patient-specific data have proven difficult to implement. It is challenging to determine which perfusion features
Externí odkaz:
https://doaj.org/article/24ba7662549d45be9485beb019a4421d
Autor:
Tim H M Huang, Elvin Blanco, Jenny C. Chang, Dong Soon Choi, Guangxu Jin, Chun Liang Chen, Wei Qian, Hong Zhao, Mauro Ferrari, Helen Wong, Yoo Shin Kim, Angel Rodriguez, Bhuvanesh Dave, Melissa D. Landis, Sergio Granados, Lacey A. Burey, Stephen T. C. Wong
Publikováno v:
Stem Cells. 32:2309-2323
Triple negative breast cancer (TNBC) is known to contain a high percentage of CD44+/CD24−/low cancer stem cells (CSCs), corresponding with a poor prognosis despite systemic chemotherapy. Chloroquine (CQ), an antimalarial drug, is a lysotropic reage
Autor:
Anil K. Sood, Yi Liu, Stephen T. C. Wong, Helen Wong, Melissa D. Landis, Lacey A. Burey, Zheng Li, Dong Soon Choi, Sergio Grandos-Principal, Jenny C. Chang, Bhuvanesh Dave, Crisitian Rodriguez-Aguayo, Wei Qian, Heidi L. Weiss
Publikováno v:
Cancer Research. 75:2312-2312
Triple negative breast cancer is characterized by its aggressive clinical behavior with high incidence of metastasis to the lungs and brain. These patients do not respond to hormonal therapy and show intrinsic resistance to conventional chemotherapy.
Publikováno v:
Cancer Research. 73:3909-3909
Chemotherapeutic delivery is generally poor in tumors characterized by rapid perfusion and low blood volume fraction. Nanoparticles can be engineered to overcome abnormal flow conditions to act as intravascular drug depots for the localized delivery
Publikováno v:
Cancer Research. 73:A91-A91
Despite the significant advances in breast cancer biology, there has been limited progress in the treatment of advanced breast cancer, with little change in the overall survival for women with metastatic breast cancer over the last several decades. T